New insider activity at Castle Biosciences ( (CSTL) ) has taken place on December 19, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Castle Biosciences’ Chief Operating Officer, Kristen M. Oelschlager, recently executed a notable insider transaction, selling 14,888 shares of the company’s stock. The total value of this sale amounts to $585,247, highlighting a sizable move by a key executive within the organization.
Recent Updates on CSTL stock
In the last 24 hours, Castle Biosciences has seen notable positive fundamental news and at least one bullish analyst reassessment. BTIG raised its price target on CSTL within a broader 2025 diagnostics/tools outlook, citing a favorable risk‑reward profile and highlighting that the company trades at a relatively low sales multiple despite what the firm views as a best‑in‑class financial profile; this reflects confidence in Castle’s revenue growth trajectory and balance of risk versus upside. On the operational side, Castle published new clinical data showing its DecisionDx-UM plus PRAME gene expression tests outperform traditional next-generation sequencing for predicting outcomes in uveal melanoma, supporting the competitive strength and clinical relevance of its portfolio. Additional publications reinforced the value of its TissueCypher Barrett’s Esophagus test in risk stratification and an expert consensus paper endorsed its DecisionDx-Melanoma test, both of which can bolster physician adoption and long-term test volume. The company also granted new inducement RSUs to 83 employees, signaling continued investment in talent and growth, though this has a limited direct effect on near-term price movement. Together, the strengthened clinical evidence base, perceived strong financial profile, and constructive risk‑reward view underpin the recent positive shift in analyst expectations for the stock.
Spark’s Take on CSTL Stock
According to Spark, TipRanks’ AI Analyst, CSTL is a Neutral.
Castle Biosciences’ overall score is driven by strong technical momentum and positive earnings call highlights, including increased revenue guidance and successful product launches. However, financial performance and valuation concerns, such as negative profitability and a high P/E ratio, weigh on the score.
To see Spark’s full report on CSTL stock, click here.
More about Castle Biosciences
YTD Price Performance: 41.23%
Average Trading Volume: 395,168
Technical Sentiment Signal: Buy
Current Market Cap: $1.16B